[Amikacin treatment of septicemia due to gentamicin-resistant gram-negative bacilli (author's transl)]. 1975

H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa

UI MeSH Term Description Entries
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011512 Proteus Infections Infections with bacteria of the genus PROTEUS. Infections, Proteus,Infection, Proteus,Proteus Infection
D011513 Proteus mirabilis A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that is frequently isolated from clinical specimens. Its most common site of infection is the urinary tract.
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002509 Cephaloridine A cephalosporin antibiotic. Cefaloridine,Cephalomycine,Cephaloridin,Ceporin
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial

Related Publications

H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
June 1977, The American journal of medicine,
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
January 1979, Bollettino dell'Istituto sieroterapico milanese,
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
January 1977, The American journal of the medical sciences,
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
January 1976, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
February 1976, Lancet (London, England),
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
June 1977, The American journal of medicine,
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
January 1971, Anesthesie, analgesie, reanimation,
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
May 1978, Archives of internal medicine,
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
February 1985, The Journal of infectious diseases,
H Tomioka, and Y Kobayashi, and S Tamatani, and T Morishita, and Y Hasegawa
November 1976, British medical journal,
Copied contents to your clipboard!